The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 3019284)

Published in Prostaglandins Leukot Essent Fatty Acids on September 24, 2010

Authors

Bruce D Levy1, Qing-yin Zhang, Caroline Bonnans, Valeria Primo, John J Reilly, David L Perkins, Yurong Liang, M Amin Arnaout, Boris Nikolic, Charles N Serhan

Author Affiliations

1: Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. blevy@partners.org

Articles cited by this

Tissue destruction by neutrophils. N Engl J Med (1989) 13.81

Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53

Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol (2001) 5.87

Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol (2007) 5.83

Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00

Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32

Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27

Ca(2+)- and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature (1995) 3.22

Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15

Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol (2000) 3.07

Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94

Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83

Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78

Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med (2002) 2.64

Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37

A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med (2008) 2.26

Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26

Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest (1993) 2.15

Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol (2005) 2.11

Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01

Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med (2005) 1.85

Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest (1998) 1.83

The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol (2009) 1.71

Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J (2007) 1.67

Improved techniques for kidney transplantation in mice. Microsurgery (1995) 1.63

Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis (1990) 1.58

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med (1999) 1.55

Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. Science (1992) 1.53

Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J (1999) 1.30

Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J (2003) 1.29

Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood (1999) 1.25

BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med (2005) 1.16

Agonist-induced lipoxin A4 generation: detection by a novel lipoxin A4-ELISA. Lipids (1993) 1.04

Human organ transplantation: background and consequences. Science (1992) 1.00

A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. FASEB J (2005) 1.00

Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J Immunol (1994) 0.98

Immunosuppressive therapy after human lung transplantation. Eur Respir J (2004) 0.96

Lipoxygenase product formation and cell adhesion during neutrophil-glomerular endothelial cell interaction. Am J Physiol (1995) 0.90

A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol (2004) 0.90

Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol (2002) 0.87

Prolonged allograft survival in TNF receptor 1-deficient recipients is due to immunoregulatory effects, not to inhibition of direct antigraft cytotoxicity. J Immunol (2002) 0.78

Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung function. Thorax (2001) 0.77

Articles by these authors

(truncated to the top 100)

Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35

Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00

TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86

Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58

Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30

Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28

Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23

Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04

Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01

Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65

Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54

A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44

Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32

Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28

Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27

Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15

Objectively measured physical activity and fat mass in a large cohort of children. PLoS Med (2007) 3.14

Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest (2006) 3.11

Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98

Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94

Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83

The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80

Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78

Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75

Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75

The ABC of Physical Activity for Health: a consensus statement from the British Association of Sport and Exercise Sciences. J Sports Sci (2010) 2.70

Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66

Fundamental movement skills and habitual physical activity in young children. Med Sci Sports Exerc (2005) 2.49

The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet (2005) 2.46

Associations between objectively measured habitual physical activity and adiposity in children and adolescents: Systematic review. Int J Pediatr Obes (2010) 2.42

Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37

Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37

Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36

Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34

Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32

Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31

Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet (2002) 2.23

The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet (2004) 2.19

Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17

Methodological considerations in using accelerometers to assess habitual physical activity in children aged 0-5 years. J Sci Med Sport (2009) 2.15

Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol (2005) 2.11

Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11

Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol (2005) 2.08

A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07

Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06

Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest (2007) 2.02

Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01

Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98

Breastfeeding and lowering the risk of childhood obesity. Lancet (2002) 1.98

Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96

The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96

Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94

Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92

Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91

Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90

Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89

Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med (2005) 1.87

MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87

Smoking during pregnancy and offspring fat and lean mass in childhood. Obesity (Silver Spring) (2006) 1.86

CT metrics of airway disease and emphysema in severe COPD. Chest (2009) 1.81

15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81

Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (2013) 1.80

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology (2014) 1.78

Longitudinal study of physical activity and sedentary behavior in children. Pediatrics (2010) 1.75

Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72

Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am J Hematol (2008) 1.71

Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70

Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol (2007) 1.69

Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol (2011) 1.69

Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68

The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2007) 1.68

Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med (2005) 1.67

Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J (2007) 1.67

Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67

Canadian Physical Activity Guidelines for the Early Years (aged 0-4 years). Appl Physiol Nutr Metab (2012) 1.67

Validity of six field and laboratory methods for measurement of body composition in boys. Obes Res (2003) 1.67

International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev (2003) 1.66

Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood (2008) 1.66

Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity (2013) 1.64

Accurate airway wall estimation using phase congruency. Med Image Comput Comput Assist Interv (2006) 1.62

Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60

Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci (2011) 1.58

The resolution of inflammation. Nat Rev Immunol (2012) 1.58

Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. J Thorac Oncol (2011) 1.57

Canadian Sedentary Behaviour Guidelines for the Early Years (aged 0-4 years). Appl Physiol Nutr Metab (2012) 1.57

Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A (2002) 1.54

Objectively measured physical activity in a representative sample of 3- to 4-year-old children. Obes Res (2003) 1.54

Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc Natl Acad Sci U S A (2010) 1.53

Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol (2012) 1.53

Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol (2003) 1.52

Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52

Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol (2008) 1.52

Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.51

Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol (2008) 1.51

Correlates of objectively measured physical activity and sedentary behaviour in English children. Eur J Public Health (2010) 1.50

Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem (2009) 1.50

Interobserver variability in the determination of upper lobe-predominant emphysema. Chest (2007) 1.49